1.A Case of Leflunomide Induced Vasculitis.
Kyu LEE ; Dong Gyu KIM ; Ji Hyun OH ; Dong Il LEE ; Choong Won LEE
The Journal of the Korean Rheumatism Association 2004;11(4):459-460
No abstract available.
Vasculitis*
2.Pulmonary vasculitis.
Tuberculosis and Respiratory Diseases 2000;48(6):825-836
No abstract available.
Vasculitis*
3.Vasculitis: Etiology and Clinical Features.
Journal of the Korean Society for Vascular Surgery 2005;21(2):190-193
No abstract available.
Vasculitis*
4.Clinical Manifestations and Significance of Mononeuritis Multiplex in Systemic Necrotizing Vasculitis.
Jinseok KIM ; Hoon Suk CHA ; Gi Hyun SEO ; Hong Joon AHN ; Chang Keun LEE ; Jae Hyun KOH ; Hyeon Sook KIM ; Dong Chull CHOI ; Eun Mi KOH
The Journal of the Korean Rheumatism Association 1999;6(1):23-30
No abstract available.
Mononeuropathies*
;
Systemic Vasculitis
;
Vasculitis*
5.Lupus Mesenteric Vasculitis Limited in Stomach.
Jae Ho LEE ; Seung Ki KWOK ; Sung Hwan PARK
Journal of Rheumatic Diseases 2012;19(4):234-235
No abstract available.
Stomach
;
Vasculitis
6.Nodular Vasculitis Associated with Cefazolin.
Jae Hwa KIM ; Joong Sun LEE ; Dae Won KOO ; Kyung Eun JUNG
Korean Journal of Dermatology 2017;55(8):553-555
No abstract available.
Cefazolin*
;
Vasculitis*
9.Treatment with Low-Dose Danazol in Livedo Vasculitis.
Korean Journal of Dermatology 1999;37(2):163-167
BACKGROUND: Several modalities have been used for the treatment of livedo vasculitis. However, in some cases conspicious morbidity is caused by recurrent painful ulceration resistant to therapy. OBJECTIVE: This study was conducted to determine the effectiveness and adverse effects of the danazol in treatment of livedo vasculitis. METHODS: Nine patients with ulcerative lesions due to livedo vasculitis were included for danazol therapy. Danazol 200mg was administered daily for 4 to 8 weeks. RESULTS: Eight of the patients showed remarkable improvement and were satisfied with this therapy. Significant adverse effects were not observed. CONCLUSION: We suggest that a low dose of danazol may be considered as the first line of treatment and is worthwhile to try in cases recalcitrant to the other treatment.
Danazol*
;
Humans
;
Ulcer
;
Vasculitis*
10.ANCA : The Marker Antibody of Vasculitis.
Journal of the Korean Medical Association 1997;40(3):344-350
No abstract available.
Antibodies, Antineutrophil Cytoplasmic*
;
Vasculitis*